Nanoformulations targeting Alzheimer's disease

Kapoor, Devesh; Sharma, Deepak; Pathak, Yashwant; Prajapati, Bhupendra Gopalbhai; Satani, Bhavik

doi:10.1016/b978-0-443-13205-6.00010-8

Alzheimer's Disease and Advanced Drug Delivery Strategies 2024

DOI: 10.1016/b978-0-443-13205-6.00010-8

|View full text |Cite

Nanoformulations targeting Alzheimer's disease

Devesh Kapoor,

Deepak Sharma,

Yashwant Pathak

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Recent developments in intranasal drug delivery of nanomedicines for the treatment of neuropsychiatric disorders

Kisku,

Nishad,

Agrawal

et al. 2024

Front. Med.

View full text Add to dashboard Cite

Neuropsychiatric disorders are multifaceted syndromes with confounding neurological explanations. It includes anxiety, depression, autism spectrum disorder, attention deficit hyperactivity disorder, schizophrenia, Tourette’s syndrome, delirium, dementia, vascular cognitive impairment, and apathy etc. Globally, these disorders occupy 15% of all diseases. As per the WHO, India has one of the largest populations of people with mental illnesses worldwide. The blood-brain barrier (BBB) makes it extremely difficult to distribute medicine to target cells in the brain tissues. However, it is possible through novel advancements in nanotechnology, molecular biology, and neurosciences. One such cutting-edge delivery method, nose-to-brain (N2B) drug delivery using nanoformulation (NF), overcomes traditional drug formulation and delivery limitations. Later offers more controlled drug release, better bioavailability, improved patient acceptance, reduced biological interference, and circumvention of BBB. When medicines are delivered via the intranasal (IN) route, they enter the nasal cavity and go to the brain via connections between the olfactory and trigeminal nerves and the nasal mucosa in N2B. Delivering phytochemical, bioactive and synthetic NF is being investigated with the N2B delivery strategy. The mucociliary clearance, enzyme degradation, and drug translocations by efflux mechanisms are significant issues associated with N2B delivery. This review article discusses the types of neuropsychiatric disorders and their treatment with plant-derived as well as synthetic drug-loaded NFs administered via the IN-delivery system. In conclusion, this review provided a comprehensive and critical overview of the IN applicability of plant-derived NFs for psychiatric disorders.

show abstract

Recent developments in intranasal drug delivery of nanomedicines for the treatment of neuropsychiatric disorders

Kisku,

Nishad,

Agrawal

et al. 2024

Front. Med.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Nanoformulations targeting Alzheimer's disease

Cited by 1 publication

References 99 publications

Recent developments in intranasal drug delivery of nanomedicines for the treatment of neuropsychiatric disorders

Recent developments in intranasal drug delivery of nanomedicines for the treatment of neuropsychiatric disorders

Contact Info

Product

Resources

About